Search
Sustainable Development - Our Commitment
Our Commitment
partnering-immunology-respiratory-diseases.pdf
AH-Partnering-CNS-Diseases.pdf
AH-Partnering-Technologies.pdf
ww-partnering-contacts_0.pdf
Boehringer Cares Patient Assistance Program Application - Spanish
Boehringer Cares Patient Assistance Program Application - English
Human Health Innovation
Pipeline
FDA Approves Stiolto® Respimat® sNDA to Add Data on COPD | BI US
FDA approves labeling for Stiolto® Respimat® (tiotropium bromide & olodaterol) with data showing reduction in COPD exacerbations. View ISI, PI & Med Guide.
Diversity
At Boeheringer Ingelheim, we believe in a diverse working culture. Find out what our people like most about working with us.
Leadership
At Boehringer Ingelheim, we recognise and celebrate strong leadership. Here’s why our people love our leadership approach.
Our Mission
Our Story
Corporate Compliance Program
Our E&C Program conforms with the principles and recommendations published in guides from various Federal agencies and industry related organizations
Cookie Statement
Cookie Statement
More Health Overview
Working at the intersection of human and animal health, we have unique opportunities to positively impact vulnerable populations.
Management Rotation
Click here to read testimonies from our employees who enrolled in our management rotation program.
New GPP Consensus Statement Released
National Psoriasis Foundation Releases Consensus Statement on Management of Generalized Pustular Psoriasis (GPP)
Express Scripts Adds BI Products to Roster | BI US
Read more on Express Scripts adding the Spiriva Respimat, Spiriva Handihaler and Stiolto Respimat to their commercial national preferred formulary.
Full results from EMPERIAL exercise ability trials presented
Full results from EMPERIAL exercise ability trials presented
US FDA accepts supplemental New Drug Application for Jardiance® for adults with chronic kidney disease
US FDA accepts supplemental New Drug Application for Jardiance® for adults with chronic kidney disease